Impax Asset Management Group
ALXN

Impax Asset Management Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Impax Asset Management Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-230,870
Closed -$42.4M – 417
2021
Q2 		$42.4M Sell
230,870
-541,779
-70% -$93M 0.19% 87
2021
Q1 		$118M Buy
772,649
+101,129
+15% +$15.6M 0.6% 58
2020
Q4 		$105M Buy
671,520
+20,230
+3% +$2.6M 0.67% 59
2020
Q3 		$74.5M Buy
651,290
+169,859
+35% +$18.3M 0.65% 56
2020
Q2 		$54M Buy
481,431
+85,991
+22% +$9.13M 0.55% 60
2020
Q1 		$35.5M Buy
395,440
+274,318
+226% +$26.9M 0.47% 61
2019
Q4 		$13.1M Buy
121,122
+57,861
+91% +$6.19M 0.15% 101
2019
Q3 		$6.2M Buy
+63,261
New +$7.13M 0.08% 148

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Impax Asset Management Group's ALXN Position: Q3 2021 in Review

Impax Asset Management Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 230,870 shares — an estimated $42.4M sold.

Impax Asset Management Group first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $118M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Impax Asset Management Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Impax Asset Management Group sold 230,870 Alexion Pharmaceuticals shares in Q3 2021, an estimated $42.4M.
  • Impax Asset Management Group first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Impax Asset Management Group's Alexion Pharmaceuticals position peaked at $118M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Impax Asset Management Group's 13F filing for Q3 2021, filed 12 Nov 2021.